Nuvation Bio Inc - Class A logo

NUVB

Nuvation Bio Inc - Class A

$2.82

Earnings Summary

Net Profits
$-34.86Mn

Highlights

Net Profits:

Nuvation Bio Inc - Class A’s net profit fell -80.3% since last year same period to $-34.86Mn in the Q2 2022. On a quarterly growth basis, Nuvation Bio Inc - Class A has generated -63.71% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Nuvation Bio Inc - Class A post its latest quarter earnings

EPS Estimate Current Quarter
-0.13
EPS Estimate Current Year
-0.13

Highlights

EPS Estimate Current Quarter:

Nuvation Bio Inc - Class A’s earning per share (EPS) estimates for the current quarter stand at -0.13 - a 7.14% jump from last quarter’s estimates.

EPS Estimate Current Year:

Nuvation Bio Inc - Class A’s earning per share (EPS) estimates for the current year stand at -0.13.

Key Ratios

Key ratios of the Nuvation Bio Inc - Class A post its Q2 2022 earnings

Return on Assets (ROA)
-0.09
Return on Equity (ROE)
-0.14
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Nuvation Bio Inc - Class A’s return on assets (ROA) stands at -0.09.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Nuvation Bio Inc - Class A’s return on equity (ROE) stands at -0.14.

Dividend Per Share (DPS):

Nuvation Bio Inc - Class A declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.14
-0.1
28.57%

Company Information

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.

Organisation
Nuvation Bio Inc - Class A
Employees
36